List of Excipients in Branded Drug SUMATRIPTAN AND NAPROXEN SODIUM

« Back to Dashboard

Generic Drugs Containing SUMATRIPTAN AND NAPROXEN SODIUM

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	sumatriptan and naproxen sodium	0378-8755	CROSPOVIDONE
Mylan Pharmaceuticals Inc	sumatriptan and naproxen sodium	0378-8755	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc	sumatriptan and naproxen sodium	0378-8755	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	sumatriptan and naproxen sodium	0378-8755	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in SUMATRIPTAN AND NAPROXEN SODIUM?

# Of NDCs	Excipient
3	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CARBOXYMETHYLCELLULOSE SODIUM
4	CELLULOSE, MICROCRYSTALLINE
4	CROSCARMELLOSE SODIUM

Sumatriptan and Naproxen Sodium Excipient Strategy and Commercial Opportunities

Last updated: October 1, 2026

Sumatriptan and naproxen sodium is a mature fixed-dose combination for acute migraine treatment. The reference product, Treximet, combines 85 mg of sumatriptan base as the succinate salt with 500 mg of naproxen sodium in a single immediate-release tablet.[1] The largest commercial opportunities are low-cost generic supply, differentiated oral delivery, improved swallowability, and lifecycle products that preserve the combination while reducing excipient, tablet-size, or tolerability problems.

The molecule pair is a small-molecule product, not a biologic. Biosimilar exposure is therefore irrelevant. Commercial risk centers on ANDA competition, Orange Book-listed patents, formulation design, manufacturing cost, and the ability to demonstrate bioequivalence for a two-active-ingredient product.

What is the composition and regulatory status of sumatriptan and naproxen sodium?

Treximet is an FDA-approved prescription tablet for the acute treatment of migraine attacks, with or without aura, in adults and pediatric patients 12 years and older.[1] It is not indicated for migraine prevention.

Attribute	Reference product
Brand	Treximet
Active ingredients	Sumatriptan succinate and naproxen sodium
Strength	85 mg sumatriptan base equivalent plus 500 mg naproxen sodium
Dosage form	Immediate-release film-coated tablet
Original applicant	Pozen, later commercialized with GlaxoSmithKline
FDA approval	2008
Regulatory pathway	NDA
Therapeutic category	Acute migraine treatment
Primary generic pathway	ANDA under section 505(j)
Biosimilar relevance	None
Key dosage-form issue	High-dose, dual-API immediate-release tablet

The product combines a serotonin 5-HT1B/1D receptor agonist with a nonsteroidal anti-inflammatory drug. Sumatriptan acts on migraine-associated cranial vasculature and trigeminal pathways. Naproxen provides anti-inflammatory and analgesic activity.[1]

The combination is commercially relevant because patients who do not obtain adequate relief from either component alone can receive both agents in one tablet. The tradeoff is a relatively large tablet, more complex analytical testing, and exposure to the contraindications and warnings of both active ingredients.

What excipients are used in Treximet and what functions do they perform?

The Treximet label identifies inactive ingredients used in the tablet core and film coat. The core excipient system is designed for immediate release, mechanical integrity, lubrication, and handling of two chemically different active ingredients.[1]

Excipient function	Typical role in this product class	Strategic objective
Dilution and compression	Microcrystalline cellulose or comparable filler	Supports tablet weight, hardness, and content uniformity
Binder	Povidone or comparable polymer	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium or comparable superdisintegrant	Promotes rapid tablet breakup
Alkalinizing or buffering support	Sodium bicarbonate or related alkaline material	Supports dissolution and microenvironmental pH
Lubrication	Magnesium stearate	Reduces ejection force
Glidancy and anti-adherence	Talc or related material	Improves powder flow and manufacturing performance
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorant	Protects the tablet and improves appearance and swallowability

The excipient strategy is constrained by the active ingredients. Naproxen sodium is a high-dose crystalline salt that contributes most of the tablet mass. Sumatriptan succinate is present at a much lower dose but can create content-uniformity and dissolution challenges. The formulation must release both actives promptly without allowing one API to dominate tablet breakup or dissolution behavior.

The label’s inactive-ingredient disclosure is the controlling source for the reference formulation. A generic sponsor does not need to replicate every excipient qualitatively or quantitatively, but the proposed formulation must meet applicable pharmaceutical equivalence and bioequivalence requirements.[1][2]

How should a generic manufacturer design the excipient system?

A successful generic formulation should prioritize rapid, reproducible disintegration and robust dissolution across physiological pH conditions. The formulation should not pursue unnecessary excipient complexity because the product is already burdened by two active ingredients and a high tablet weight.

Managing the high naproxen sodium load

Naproxen sodium is likely to determine tablet dimensions, compression behavior, and manufacturing throughput. The formulation should use a high-functionality filler or direct-compression grade where possible. Granulation may improve flow and content uniformity, but it adds processing time and moisture exposure.

Important development variables include:

• Particle-size distribution of naproxen sodium.
• Crystal habit and polymorphic control.
• Bulk and tapped density.
• Compression force and ejection stress.
• Lubricant concentration and blending time.
• Tablet tensile strength versus disintegration time.
• Sensitivity to humidity during storage.

Over-lubrication can slow wetting and dissolution. Excessive compression can produce a hard tablet that meets friability specifications but disintegrates too slowly.

Protecting sumatriptan content uniformity

The lower-dose sumatriptan component creates a distribution problem within a tablet dominated by naproxen sodium. A manufacturer should evaluate ordered mixing, dry granulation, wet granulation, or separate granulation of the two APIs.

Separate processing can reduce segregation if the APIs differ materially in density or particle size. It also increases process complexity and may create a risk of nonuniform distribution at the interface between granules.

Analytical development should quantify both actives in blend, compression-stage, and finished-product samples. Assay alone is insufficient. The development package should evaluate individual-unit content uniformity and dissolution profiles for each API.

Controlling microenvironmental pH

A pH modifier can materially affect the dissolution of both components. Alkaline excipients may improve the apparent dissolution environment for naproxen, but excessive alkalinity can alter the stability or dissolution behavior of sumatriptan.

The formulation should use a controlled buffer capacity rather than a large excess of alkalizing material. Compatibility studies should evaluate:

• API-excipient degradation.
• Water activity and moisture uptake.
• Dissolution at multiple pH values.
• Stability under accelerated conditions.
• Changes in impurity profiles.
• Interaction with film-coat components.

Achieving rapid disintegration

Croscarmellose sodium, crospovidone, and sodium starch glycolate are potential disintegrant platforms. The choice should be based on tablet hardness, lubricant sensitivity, and dissolution performance rather than on disintegration time alone.

A wicking-based system can be useful for a large, dense tablet. However, excessive compression or hydrophobic lubricant coverage can negate the benefit of a superdisintegrant. The target should be consistent breakup and rapid release of both APIs.

What formulation patents protect sumatriptan and naproxen sodium?

The key intellectual-property issue is the product-specific estate around Treximet, not patent protection for the old active ingredients themselves. Sumatriptan and naproxen sodium were disclosed and commercialized well before Treximet. Their composition-of-matter protection is therefore no longer the primary barrier to generic entry.

Historically relevant protection has included patents directed to:

• The combination of sumatriptan and naproxen.
• Ratios and dosage strengths.
• Oral solid formulations.
• Treatment of migraine using the combination.
• Manufacturing or formulation attributes affecting release.

The reference product’s FDA regulatory history and Orange Book records are the appropriate sources for identifying listed patents, pediatric exclusivity, and any remaining listing status.[2][3] Patent expiration must be assessed patent by patent because expiration can differ by filing date, patent-term adjustment, terminal disclaimer, and pediatric extension.

What is the Orange Book status of Treximet?

Treximet’s five-year new chemical entity exclusivity period is no longer a commercial barrier. The product was approved in 2008, and the NCE exclusivity period would ordinarily have ended in 2013, subject to applicable regulatory adjustments. Pediatric exclusivity could extend listed exclusivity by six months if granted.[2][3]

The practical generic-entry question is whether any unexpired, properly listed formulation or method-of-use patent remains enforceable against the proposed ANDA product. A generic applicant may:

1. File a Paragraph III certification and wait for patent expiry.
2. File a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.
3. Carve out a patented method of use where FDA labeling permits a noninfringing indication.
4. Use a formulation that avoids a claim directed to a specific excipient, ratio, release profile, or process.

For a mature small-molecule combination, the commercial value of a Paragraph IV strategy depends less on the age of the brand and more on the scope and enforceability of the remaining claims.

When does sumatriptan and naproxen sodium lose exclusivity?

Regulatory exclusivity has already expired. The meaningful entry barriers are patent-specific and manufacturing-specific.

Exclusivity or barrier	Commercial relevance
Sumatriptan NCE protection	Expired
Naproxen NCE protection	Expired
Treximet NCE exclusivity	Expired
Pediatric extension	Historical, no longer a standalone barrier
Product-specific patents	Must be reviewed against current Orange Book records
ANDA approval	Depends on patent certification, bioequivalence, labeling, and manufacturing readiness
Clinical differentiation	Usually not needed for a conventional ANDA
Supply-chain qualification	Material for launch reliability and pharmacy substitution

Generic entry can occur before the ultimate patent expiry if an applicant prevails in patent litigation, reaches a settlement permitting launch, or uses a noninfringing design.

What Paragraph IV challenges and patent litigation affect Treximet?

The principal litigation risk arises when an ANDA applicant files a Paragraph IV certification against an Orange Book-listed Treximet patent. A Paragraph IV notice can trigger a 45-day period for the patent holder to file suit. A timely suit may impose a 30-month stay of FDA approval, subject to statutory exceptions and court decisions.[4]

The relevant litigation questions are:

• Which patents were listed for the reference product at the time of ANDA filing?
• Were the asserted claims directed to the proposed generic product?
• Did the generic formulation use the claimed salt, ratio, excipient, or process?
• Was the claimed method of use carved out of the proposed label?
• Did the brand owner settle for a delayed launch?
• Did the court find the claims valid, infringed, invalid, or not infringed?

Because Treximet is a mature product, later entrants may have limited incentive to pursue expensive litigation unless the market supports several manufacturers or a first-filer opportunity. A settlement can still affect launch timing and market share, particularly if one applicant obtains a controlled early-entry date.

What commercial opportunities exist for excipient-led products?

The strongest opportunities are practical rather than patent-dependent. A sponsor can improve manufacturing economics, patient handling, or adherence without changing the therapeutic concept.

Lower-cost immediate-release tablets

A conventional generic tablet can compete on:

• Lower manufacturing cost.
• Reliable supply.
• Simplified coating.
• Fewer specialty excipients.
• High-throughput direct compression.
• Multiple pack sizes for retail and mail-order channels.

The main risk is tablet size. A formulation that reduces excipient mass but increases hardness or slows disintegration can fail to match the reference product’s dissolution behavior.

Smaller or easier-to-swallow tablets

The 500 mg naproxen sodium load limits tablet-size reduction. Opportunities include higher-density excipient systems, optimized particle engineering, and compression processes that reduce void volume.

A smaller tablet may improve patient acceptance, but it must preserve rapid release and avoid excessive compression force. A caplet or oval tablet can improve swallowability without materially changing formulation composition.

Orally disintegrating or chewable products

An orally disintegrating tablet could address patients with migraine-associated nausea or difficulty swallowing. The technical challenges are substantial:

• Naproxen sodium has a high dose and can create a large ODT.
• Both APIs may have strong or unpleasant taste characteristics.
• Taste masking can delay dissolution.
• A fragile ODT may suffer from packaging and shipping losses.
• Bioequivalence may be more complex if the product is administered without water.

A chewable product requires robust taste masking and clear administration instructions. These products are better suited to a 505(b)(2) lifecycle strategy than to a conventional ANDA unless the dosage form and labeling fit an existing reference-product pathway.

Sachets, powders, and liquid dispersions

A powder or granule formulation could reduce swallowing difficulty and support rapid dispersion. Naproxen sodium’s water solubility is favorable relative to naproxen acid, but palatability, moisture protection, dose uniformity, and packaging become central issues.

Unit-dose sachets may create a differentiated commercial product for urgent-use settings, telehealth fulfillment, and travel. The product would face more extensive packaging and stability work than a conventional tablet.

Combination products with packaging or adherence differentiation

Commercial opportunities include:

• Calendar or unit-dose blister packaging.
• Travel packs.
• Pediatric-age-appropriate presentation where legally and clinically appropriate.
• Pharmacy-ready adherence packs.
• Lower-cost authorized-generic distribution.
• Digital prescription fulfillment tied to migraine treatment programs.

Packaging does not usually create meaningful drug patent protection, but it can support a branded-generic price premium if the patient or payer values convenience.

How strong is the patent estate compared with the commercial opportunity?

The patent estate is weaker than the commercial opportunity for a new entrant because the active ingredients and regulatory exclusivity are mature. The product can still support revenue if the entrant controls manufacturing cost and secures dependable distribution.

Factor	Assessment
Composition-of-matter protection	Low
Regulatory exclusivity	Expired
Formulation-patent risk	Requires claim-by-claim review
ANDA development complexity	Moderate
Analytical burden	High because two APIs must be controlled
Tablet manufacturing difficulty	Moderate to high
Biosimilar risk	None
Price erosion risk	High after multiple generic entrants
Differentiated dosage-form opportunity	Moderate
Manufacturing barrier	Meaningful but manageable
Licensing value	Highest for formulation technology, supply, or distribution

The best investment case is usually a low-cost, scalable generic with a defensible supply position. A premium product needs a meaningful advantage in administration, tolerability, packaging, or access.

How does sumatriptan and naproxen sodium compare with separate generic therapy?

The combination competes with separate generic sumatriptan and naproxen products, which are usually cheaper on an ingredient basis and offer dose flexibility.

Issue	Fixed-dose combination	Separate products
Convenience	One tablet	Two products
Dose flexibility	Limited to marketed strength	Greater
Manufacturing	More complex	Simpler per product
Pharmacy substitution	Depends on exact product	Broad generic availability
Patient adherence	Potentially better	More administration steps
Tablet burden	Lower	Higher
Commercial pricing	Can support a premium if convenient	Strong price pressure
Clinical positioning	Single-product acute treatment	Flexible component therapy

The fixed-dose product is most defensible where convenience, adherence, and rapid access matter. It is less competitive when payers evaluate only ingredient cost.

What licensing and partnership strategies are available?

The original Treximet commercialization model demonstrates the value of combining formulation development with a larger commercial platform. The product was developed through Pozen and commercialized through a larger pharmaceutical partner, illustrating a common licensing structure for combination products.[5]

Potential transactions include:

• Licensing an optimized immediate-release formulation to a generic manufacturer.
• Supplying a qualified dual-API blend or granulation intermediate.
• Out-licensing an ODT, chewable, or powder formulation.
• Partnering with a migraine-focused telehealth or specialty-pharmacy channel.
• Granting regional rights where prescription access and generic competition differ.
• Acquiring an authorized-generic or private-label distribution position.

A license is more valuable when it transfers validated manufacturing know-how, analytical methods, stability data, and regulatory documentation. A bare formulation patent has less value if multiple noninfringing generic designs are available.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Single entrant

The first approved generic may capture significant volume before price erosion accelerates. The opportunity depends on the absence of a blocking stay, commercial inventory, payer acceptance, and pharmacy substitution.

Multi-entrant launch

Several approved ANDAs can produce rapid price compression. In this scenario, manufacturing cost, service levels, and wholesaler relationships determine share more than formulation differentiation.

Branded-generic or differentiated launch

A sponsor can preserve pricing through an easier-to-swallow tablet, specialty packaging, or an alternative dosage form. This strategy requires evidence that prescribers, pharmacies, or patients value the improvement.

What manufacturing and IP barriers remain?

The major barriers are process and regulatory execution rather than basic API access.

A manufacturer must control:

• API segregation during blending and compression.
• Dual-API assay and impurity methods.
• Naproxen sodium particle properties.
• Moisture exposure and packaging protection.
• Tablet hardness and disintegration.
• Dissolution of each active across pH conditions.
• Film-coat uniformity.
• Scale-up reproducibility.
• Stability under long-term and accelerated conditions.
• Commercial supply of both APIs.

A formulation that is easy to make at laboratory scale may fail during high-speed compression because of segregation, sticking, capping, or lubricant sensitivity. These risks can be reduced through particle engineering, controlled granulation, and robust in-process testing.

Key Takeaways

• Sumatriptan and naproxen sodium is a mature small-molecule fixed-dose combination, not a biologic.
• Treximet contains 85 mg of sumatriptan base equivalent and 500 mg of naproxen sodium in an immediate-release tablet.
• NCE and regulatory exclusivity barriers have expired; remaining patent risk is product-specific.
• The core formulation challenge is combining a low-dose API with a high-dose naproxen sodium load while maintaining rapid, reproducible release.
• Excipient strategy should emphasize direct compression or efficient granulation, controlled microenvironmental pH, rapid disintegration, and strong content uniformity.
• Conventional generic tablets offer the clearest commercial path, but price erosion will be substantial with multiple entrants.
• ODT, chewable, powder, and improved-swallowability products offer higher-margin opportunities but may require a 505(b)(2) strategy.
• Biosimilar competition does not apply.
• The strongest defensibility is likely to come from manufacturing cost, supply reliability, dosage-form usability, and distribution rather than composition-of-matter patents.

FAQs

Can a generic use different excipients from Treximet?

Yes. A generic applicant may use a different qualitative or quantitative excipient composition if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, labeling, and manufacturing requirements.

Is naproxen sodium the main driver of tablet size?

Yes. The 500 mg naproxen sodium dose contributes most of the active mass and is the primary constraint on tablet dimensions and compression design.

Is a sumatriptan-naproxen ODT commercially attractive?

Potentially. An ODT could address swallowing difficulty and migraine-associated nausea, but the high naproxen sodium dose, taste masking, tablet size, mechanical strength, and regulatory pathway make development materially more complex than a standard tablet.

Does the product face biosimilar competition?

No. Sumatriptan and naproxen sodium are chemically synthesized small molecules. The relevant competitive pathway is generic ANDA approval, not biosimilar approval.

What is the most defensible commercial strategy?

A low-cost immediate-release generic with reliable supply is the most direct strategy. A smaller tablet, taste-masked product, unit-dose presentation, or alternative oral dosage form can support differentiation if the sponsor can justify the added development and regulatory cost.

References

1. U.S. Food and Drug Administration. (2023). Treximet (sumatriptan succinate and naproxen sodium) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Treximet.
4. U.S. Food and Drug Administration. (2023). ANDA submissions: Refuse-to-receive standards and Paragraph IV patent certifications.
5. Pozen Inc. (2008). Annual report and corporate disclosures concerning Treximet development and commercialization.